Results 231 to 240 of about 308,594 (267)
Some of the next articles are maybe not open access.
Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.
Cancer research, 1991We have probed for the presence of interleukin 6 (IL6) receptors in prostatic carcinoma cell lines (LNCaP, DU 145, and PC3) by examining their sensitivity to the cytotoxic effects of a chimeric toxin composed of IL6 and Pseudomonas exotoxin (PE). All three cell lines were killed by IL6-PE66(4)Glu, a version of IL6-PE in which the binding domain of ...
C B, Siegall +4 more
openaire +1 more source
Tocilizumab: The first interleukin-6-receptor inhibitor
American Journal of Health-System Pharmacy, 2008The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed.Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R).
openaire +2 more sources
Interleukin-6 Receptor and Signals
Chemical immunology, 1992Tetsuya Taga +10 more
openaire +3 more sources
European cytokine network, 1998
An sIL-6R/IL-6 chimera, directly fusing the natural forms of soluble IL-6 receptor and IL-6, as found in human body fluids, was produced in transfected human cells. The secreted p85 glycoprotein was active at a concentration of 120 pM to produce growth-arrest and spindleoid differentiation of murine melanoma F10.9 cells, which do not respond to IL-6 ...
J, Chebath +10 more
openaire +1 more source
An sIL-6R/IL-6 chimera, directly fusing the natural forms of soluble IL-6 receptor and IL-6, as found in human body fluids, was produced in transfected human cells. The secreted p85 glycoprotein was active at a concentration of 120 pM to produce growth-arrest and spindleoid differentiation of murine melanoma F10.9 cells, which do not respond to IL-6 ...
J, Chebath +10 more
openaire +1 more source
The Soluble Interleukin‐6 Receptora
Annals of the New York Academy of Sciences, 1995S, Rose-John +3 more
openaire +2 more sources
European cytokine network, 1999
Interleukin-6 (IL-6) is used as a growth factor by various tumor cells. It binds to a gp80 specific receptor (IL-6R) and then to a gp130 transducing chain. Both receptor chains are released as soluble functional proteins which circulate in biological fluids.
J P, Gaillard +4 more
openaire +1 more source
Interleukin-6 (IL-6) is used as a growth factor by various tumor cells. It binds to a gp80 specific receptor (IL-6R) and then to a gp130 transducing chain. Both receptor chains are released as soluble functional proteins which circulate in biological fluids.
J P, Gaillard +4 more
openaire +1 more source
European cytokine network, 2001
Multiple myeloma (MM) is a plasma-cell disorder in which malignant plasma cells accumulate in the bone marrow and usually produce a monoclonal immunoglobulin. Usual presenting features of overt MM include recurrent osteolytic lesions, bacterial infections, anemia and renal insufficiency.
S, Barillé, R, Bataille, M, Amiot
openaire +1 more source
Multiple myeloma (MM) is a plasma-cell disorder in which malignant plasma cells accumulate in the bone marrow and usually produce a monoclonal immunoglobulin. Usual presenting features of overt MM include recurrent osteolytic lesions, bacterial infections, anemia and renal insufficiency.
S, Barillé, R, Bataille, M, Amiot
openaire +1 more source
INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR IN SURGICAL TRAUMA
Shock, 1995Michio Ogawa +4 more
openaire +1 more source
[Interleukin-6/soluble interleukin-6 receptor].
Nihon rinsho. Japanese journal of clinical medicine, 2000A, Yokoyama, K, Hiwada
openaire +1 more source